Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei City, Taiwan.
Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
J Biomed Sci. 2019 Sep 3;26(1):65. doi: 10.1186/s12929-019-0560-7.
Enterovirus A71 (EV-A71) is an important emerging virus posing a threat to children under five years old. EV-A71 infection in infants or young children can cause hand-foot-and-mouth disease, herpangina, or severe neurological complications. However, there are still no effective antivirals for treatment of these infections. In this review, we summarize the antiviral compounds developed to date based on various targets of the EV-A71 life cycle. Moreover, development of a vaccine would be the most effective approach to prevent EV-A71 infection. Therefore, we also summarize the development and clinical progress of various candidate EV-A71 vaccines, including inactivated whole virus, recombinant VP1 protein, synthetic peptides, viral-like particles, and live attenuated vaccines.
肠道病毒 A71 型（EV-A71）是一种重要的新兴病毒，对五岁以下儿童构成威胁。婴儿或幼儿感染 EV-A71 可引起手足口病、疱疹性咽峡炎或严重的神经并发症。然而，目前针对这些感染还没有有效的抗病毒药物。在这篇综述中，我们根据 EV-A71 生命周期的各种靶点，总结了迄今为止开发的抗病毒化合物。此外，疫苗的开发将是预防 EV-A71 感染最有效的方法。因此，我们还总结了各种候选 EV-A71 疫苗的开发和临床进展，包括灭活全病毒、重组 VP1 蛋白、合成肽、病毒样颗粒和减毒活疫苗。
